Ion-exchange resin anticoagulation (i-ERA) : a novel extracorporeal technique for regional anticoagulation

BACKGROUND: Extracorporeal treatments always require blood anticoagulation. We tested feasibility and efficacy of a novel technique for regional extracorporeal blood anticoagulation based on calcium removal by ion-exchange resins (i-ER), called ion-exchange resin anticoagulation (i-ERA). METHODS: Eight swine were connected to a veno-venous extracorporeal circuit comprising a hemodiafilter and an i-ER. Blood flow was 150\u200amL/min. Hemodiafiltrate was generated at 975\u200amL/min and passed through the i-ER. A fraction of the calcium-free hemodiafiltrate was returned to the hemodiafilter (675\u200amL/min) while the remaining was re-circulated prior the hemodiafilter (300\u200amL/min) to dilute blood entering the hemodiafilter. A calcium replacement solution was continuously infused. Two hours after i-ERA start, blood was sampled from inlet, before the hemodiafilter (pre-hemodiafilter blood) and from outlet of the extracorporeal circuit for iCa concentration and thromboelastography (TEG). Arterial blood was collected for blood gas analyses, electrolytes concentrations and free hemoglobin. Hemodynamics and ventilation were monitored. RESULTS: i-ERA reduced iCa from 1.28\u200a\ub1\u200a0.05\u200ammol/L (inlet) to 0.47\u200a\ub1\u200a0.03\u200ammol/L (pre-hemodiafilter blood) and 0.25\u200a\ub1\u200a0.03\u200ammol/L (outlet). Pre-hemodiafilter blood and outlet samples showed no sign of clot formation (reaction time (R)\u200a>\u200a60\u200amin; maximal amplitude (MA)\u200a=\u200a0 (0-0) mm), while blood-inlet had normal coagulation (R\u200a=\u200a8.5 (5.8-10.2) min; MA\u200a=\u200a65.2 (63.2-68.7) mm). Arterial gas analyses and electrolytes concentrations, hemodynamics and ventilation were unchanged. No hemolysis was recorded. CONCLUSIONS: In a swine model, i-ERA proved feasible and effective in reducing iCa and preventing clot formation with TEG analyses. Further studies are warranted to evaluate the long-term efficacy and safety of i-ERA. LEVEL OF EVIDENCE: V-therapeutic animal experiment